Pittsford, NY, United States of America

Hakjoo Lee

This inventor holds 6 USPTO granted patents and 1 published patent application. Top assignee: Tumor Biology Investment Group, Inc.. Active years: 2008-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hakjoo Lee. Retrieved from https://idiyas.com/inventor/hakjoo-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 6 

Average Co-Inventor Count = 2.0

ph-index = 5

Forward Citations = 43(Granted Patents)


Location History:

  • Rochester, MN (US) (2008 - 2009)
  • Pittsford, NY (US) (2009 - 2010)

Company Filing History:


Years Active: 2008-2010

Loading Chart...
6 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Hakjoo Lee: Advancements in Cancer Therapeutics**

Introduction

Hakjoo Lee, an esteemed inventor based in Pittsford, NY, has made significant strides in the field of cancer research. With a remarkable portfolio of six patents, Lee's innovative methods and discoveries have the potential to reshape cancer diagnostics and therapeutics. His latest patents focus on soluble ErbB3 and its implications in cancer treatment and detection, showcasing his dedication to tackling one of the most pressing healthcare challenges.

Latest Patents

Hakjoo Lee's latest patents delve into "Soluble ErbB3 methods of detection and antibodies." These patents detail the regulation of sErbB3 isoforms to influence heregulin activity or ErbB receptor activities. Furthermore, they outline cancer therapeutics and methods for treating cancer that utilize sErbB3. The patents expound on the detection of sErbB3 in biological samples, facilitating risk assessment and prevention, screening, diagnosis, prognosis, theragnosis, and the evaluation of responsiveness to treatment. Additionally, they emphasize the importance of monitoring disease progression, recurrence, or metastasis of cancer. In practical applications, the patents highlight the use of sErbB3 nucleic acid sequences, polypeptides, molecular probes, and antibodies as pivotal agents for regulation, expression, detection, and cancer therapeutics associated with sErbB3.

Career Highlights

Hakjoo Lee is currently affiliated with Tumor Biology Investment Group, Inc., where he leverages his expertise to push for innovations in oncology. His extensive work in researching cancer mechanisms and therapies continues to contribute to advancements in understanding and treating this devastating disease.

Collaborations

In his career, Hakjoo Lee has collaborated closely with Nita J. Maihle, a fellow researcher in the field. Their partnership reflects a strong commitment to enhancing cancer research and developing effective therapeutic methods, paving the way for future innovations.

Conclusion

As an inventor, Hakjoo Lee exemplifies the spirit of innovation within the medical research community. His contributions to the understanding of sErbB3 and its role in cancer provide hope for new diagnostic and therapeutic options. Through his work, he continues to inspire future generations of researchers and inventors dedicated to fighting against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…